市場調査レポート
商品コード
1234265

BCL-2(B細胞リンパ腫2)阻害剤の世界市場 2023-2027

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 166 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
BCL-2(B細胞リンパ腫2)阻害剤の世界市場 2023-2027
出版日: 2023年02月21日
発行: TechNavio
ページ情報: 英文 166 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Technavio社は、BCL-2(B細胞リンパ腫2)阻害剤の市場規模は、2022年から2027年の間に16億5,708万米ドルの増加が見込まれ、予測期間中に12.92%のCAGRで成長すると予測しています。

当レポートでは、BCL-2(B細胞リンパ腫2)阻害剤市場について、全体的な分析、市場規模・予測、動向、成長促進要因・課題、約25のベンダーを網羅したベンダー分析などを掲載しています。

現在の市場シナリオ、最新動向と促進要因、市場全体の環境に関する最新の分析を提供しています。市場は、老年人口の増加、血液悪性腫瘍に関する意識の高まり、BCL-2阻害剤の高い標的親和性と特異性によって牽引されています。

本調査では、患者支援プログラムの増加が、今後数年間のBCL-2(B細胞リンパ腫2)阻害剤市場の成長を促進する主要な理由の1つであると特定しています。また、併用療法の承認が進み、新規製剤の開発が進んでいることも、市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し:2022-2027年の予測

第4章 市場規模実績

  • 世界のBCL-2(B細胞リンパ腫2)阻害剤市場2017年~2021年
  • 製品セグメント分析2017-2021
  • タイプセグメント分析2017-2021
  • 地域セグメント分析2017-2021
  • 国セグメント分析2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 製品別の市場セグメンテーション

  • 市場セグメント
  • 製品別比較
  • 併用療法 - 市場規模と予測 2022-2027
  • 単剤療法 - 市場規模と予測 2022-2027
  • 製品別の市場機会

第7章 タイプ別の市場セグメンテーション

  • 市場セグメント
  • タイプ別比較
  • びまん性大細胞型B細胞性リンパ腫(DLBCL) - 市場規模と予測 2022-2027
  • 濾胞性リンパ腫 - 市場規模と予測 2022-2027
  • 慢性リンパ性白血病 - 市場規模と予測 2022-2027
  • マントル細胞リンパ腫(MCL) - 市場規模と予測 2022-2027
  • タイプ別の市場機会

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 - 市場規模と予測 2022-2027
  • 欧州 - 市場規模と予測 2022-2027
  • アジア - 市場規模と予測 2022-2027
  • その他の地域(ROW) - 市場規模と予測 2022-2027
  • 米国 - 市場規模と予測 2022-2027
  • カナダ - 市場規模と予測 2022-2027
  • ドイツ - 市場規模と予測 2022-2027
  • 英国 - 市場規模と予測 2022-2027
  • フランス - 市場規模と予測 2022-2027
  • 地域別の市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AbbVie Inc.
  • Abcam plc
  • Amgen Inc.
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bio Techne Corp.
  • Biorbyt Ltd.
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Merck and Co. Inc.
  • Novartis AG
  • Santa Cruz Biotechnology Inc.
  • Seagen Inc.
  • Servier

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market by Geography
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Product
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Type
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Product - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Product - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Product
  • Exhibits33: Data Table on Comparison by Product
  • Exhibits34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Market opportunity by Product ($ million)
  • Exhibits43: Data Table on Market opportunity by Product ($ million)
  • Exhibits44: Chart on Type - Market share 2022-2027 (%)
  • Exhibits45: Data Table on Type - Market share 2022-2027 (%)
  • Exhibits46: Chart on Comparison by Type
  • Exhibits47: Data Table on Comparison by Type
  • Exhibits48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibits49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibits50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
  • Exhibits51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
  • Exhibits52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
  • Exhibits54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
  • Exhibits56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
  • Exhibits58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
  • Exhibits60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibits61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibits62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
  • Exhibits63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
  • Exhibits64: Market opportunity by Type ($ million)
  • Exhibits65: Data Table on Market opportunity by Type ($ million)
  • Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits67: Chart on Market share by geography 2022-2027 (%)
  • Exhibits68: Data Table on Market share by geography 2022-2027 (%)
  • Exhibits69: Chart on Geographic comparison
  • Exhibits70: Data Table on Geographic comparison
  • Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits93: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits97: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits99: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits101: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits102: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits103: Chart on France - Market size and forecast 2022-2027 ($ million)
  • Exhibits104: Data Table on France - Market size and forecast 2022-2027 ($ million)
  • Exhibits105: Chart on France - Year-over-year growth 2022-2027 (%)
  • Exhibits106: Data Table on France - Year-over-year growth 2022-2027 (%)
  • Exhibits107: Market opportunity by geography ($ million)
  • Exhibits108: Data Tables on Market opportunity by geography ($ million)
  • Exhibits109: Impact of drivers and challenges in 2022 and 2027
  • Exhibits110: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits111: Overview on factors of disruption
  • Exhibits112: Impact of key risks on business
  • Exhibits113: Vendors covered
  • Exhibits114: Matrix on vendor position and classification
  • Exhibits115: AbbVie Inc. - Overview
  • Exhibits116: AbbVie Inc. - Product / Service
  • Exhibits117: AbbVie Inc. - Key news
  • Exhibits118: AbbVie Inc. - Key offerings
  • Exhibits119: Abcam plc - Overview
  • Exhibits120: Abcam plc - Product / Service
  • Exhibits121: Abcam plc - Key news
  • Exhibits122: Abcam plc - Key offerings
  • Exhibits123: Amgen Inc. - Overview
  • Exhibits124: Amgen Inc. - Product / Service
  • Exhibits125: Amgen Inc. - Key offerings
  • Exhibits126: Ascentage Pharma Group International - Overview
  • Exhibits127: Ascentage Pharma Group International - Product / Service
  • Exhibits128: Ascentage Pharma Group International - Key offerings
  • Exhibits129: AstraZeneca Plc - Overview
  • Exhibits130: AstraZeneca Plc - Product / Service
  • Exhibits131: AstraZeneca Plc - Key news
  • Exhibits132: AstraZeneca Plc - Key offerings
  • Exhibits133: BeiGene Ltd. - Overview
  • Exhibits134: BeiGene Ltd. - Business segments
  • Exhibits135: BeiGene Ltd. - Key offerings
  • Exhibits136: BeiGene Ltd. - Segment focus
  • Exhibits137: Bio Techne Corp. - Overview
  • Exhibits138: Bio Techne Corp. - Business segments
  • Exhibits139: Bio Techne Corp. - Key news
  • Exhibits140: Bio Techne Corp. - Key offerings
  • Exhibits141: Bio Techne Corp. - Segment focus
  • Exhibits142: Biorbyt Ltd. - Overview
  • Exhibits143: Biorbyt Ltd. - Product / Service
  • Exhibits144: Biorbyt Ltd. - Key offerings
  • Exhibits145: Bristol Myers Squibb Co. - Overview
  • Exhibits146: Bristol Myers Squibb Co. - Product / Service
  • Exhibits147: Bristol Myers Squibb Co. - Key news
  • Exhibits148: Bristol Myers Squibb Co. - Key offerings
  • Exhibits149: F. Hoffmann La Roche Ltd. - Overview
  • Exhibits150: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibits151: F. Hoffmann La Roche Ltd. - Key news
  • Exhibits152: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibits153: F. Hoffmann La Roche Ltd. - Segment focus
  • Exhibits154: Merck and Co. Inc. - Overview
  • Exhibits155: Merck and Co. Inc. - Business segments
  • Exhibits156: Merck and Co. Inc. - Key news
  • Exhibits157: Merck and Co. Inc. - Key offerings
  • Exhibits158: Merck and Co. Inc. - Segment focus
  • Exhibits159: Novartis AG - Overview
  • Exhibits160: Novartis AG - Business segments
  • Exhibits161: Novartis AG - Key offerings
  • Exhibits162: Novartis AG - Segment focus
  • Exhibits163: Santa Cruz Biotechnology Inc. - Overview
  • Exhibits164: Santa Cruz Biotechnology Inc. - Product / Service
  • Exhibits165: Santa Cruz Biotechnology Inc. - Key offerings
  • Exhibits166: Seagen Inc. - Overview
  • Exhibits167: Seagen Inc. - Product / Service
  • Exhibits168: Seagen Inc. - Key offerings
  • Exhibits169: Servier - Overview
  • Exhibits170: Servier - Business segments
  • Exhibits171: Servier - Key offerings
  • Exhibits172: Servier - Segment focus
  • Exhibits173: Inclusions checklist
  • Exhibits174: Exclusions checklist
  • Exhibits175: Currency conversion rates for US$
  • Exhibits176: Research methodology
  • Exhibits177: Validation techniques employed for market sizing
  • Exhibits178: Information sources
  • Exhibits179: List of abbreviations
目次
Product Code: IRTNTR72723

Technavio has been monitoring the BCL-2 (B-cell Lymphoma 2) inhibitors market and is forecast to grow by $1,657.08 mn during 2022-2027, accelerating at a CAGR of 12.92% during the forecast period. Our report on the BCL-2 (B-cell Lymphoma 2)inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors.

Technavio's BCL-2 (B-cell Lymphoma 2) inhibitors market is segmented as below:

By Product

  • Combination therapy
  • Monotherapy

By Type

  • Diffuse large B-cell lymphoma (DLBCL)
  • Follicular lymphoma
  • Chronic lymphocytic leukemia
  • Mantle cell lymphoma (MCL)

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the increase of patient assistance programs as one of the prime reasons driving the BCL-2 (B-cell Lymphoma 2) inhibitors market growth during the next few years. Also, growing approval of combination therapy and development of novel formulations will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the BCL-2 (B-cell Lymphoma 2) inhibitors market covers the following areas:

  • BCL-2 (B-cell Lymphoma 2) inhibitors market sizing
  • BCL-2 (B-cell Lymphoma 2) inhibitors market forecast
  • BCL-2 (B-cell Lymphoma 2) inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading BCL-2 (B-cell Lymphoma 2) inhibitors market vendors that include Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, and AbbVie Inc. Also, the BCL-2 (B-cell Lymphoma 2) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market by Geography
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million)
  • 4.2 Product Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Product Segment 2017 - 2021 ($ million)
  • 4.3 Type Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

  • 6.1 Market segments
  • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
  • 6.2 Comparison by Product
  • Exhibit 32: Chart on Comparison by Product
  • Exhibit 33: Data Table on Comparison by Product
  • 6.3 Combination therapy - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
  • 6.4 Monotherapy - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Product
  • Exhibit 42: Market opportunity by Product ($ million)
  • Exhibit 43: Data Table on Market opportunity by Product ($ million)

7 Market Segmentation by Type

  • 7.1 Market segments
  • Exhibit 44: Chart on Type - Market share 2022-2027 (%)
  • Exhibit 45: Data Table on Type - Market share 2022-2027 (%)
  • 7.2 Comparison by Type
  • Exhibit 46: Chart on Comparison by Type
  • Exhibit 47: Data Table on Comparison by Type
  • 7.3 Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027
  • Exhibit 48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
  • Exhibit 51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
  • 7.4 Follicular lymphoma - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
  • 7.5 Chronic lymphocytic leukemia - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
  • 7.6 Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027
  • Exhibit 60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
  • Exhibit 63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
  • 7.7 Market opportunity by Type
  • Exhibit 64: Market opportunity by Type ($ million)
  • Exhibit 65: Data Table on Market opportunity by Type ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
  • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 69: Chart on Geographic comparison
  • Exhibit 70: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Canada - Market size and forecast 2022-2027
  • Exhibit 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.9 Germany - Market size and forecast 2022-2027
  • Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.10 UK - Market size and forecast 2022-2027
  • Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.11 France - Market size and forecast 2022-2027
  • Exhibit 103: Chart on France - Market size and forecast 2022-2027 ($ million)
  • Exhibit 104: Data Table on France - Market size and forecast 2022-2027 ($ million)
  • Exhibit 105: Chart on France - Year-over-year growth 2022-2027 (%)
  • Exhibit 106: Data Table on France - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography
  • Exhibit 107: Market opportunity by geography ($ million)
  • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 111: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 112: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 113: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 114: Matrix on vendor position and classification
  • 12.3 AbbVie Inc.
  • Exhibit 115: AbbVie Inc. - Overview
  • Exhibit 116: AbbVie Inc. - Product / Service
  • Exhibit 117: AbbVie Inc. - Key news
  • Exhibit 118: AbbVie Inc. - Key offerings
  • 12.4 Abcam plc
  • Exhibit 119: Abcam plc - Overview
  • Exhibit 120: Abcam plc - Product / Service
  • Exhibit 121: Abcam plc - Key news
  • Exhibit 122: Abcam plc - Key offerings
  • 12.5 Amgen Inc.
  • Exhibit 123: Amgen Inc. - Overview
  • Exhibit 124: Amgen Inc. - Product / Service
  • Exhibit 125: Amgen Inc. - Key offerings
  • 12.6 Ascentage Pharma Group International
  • Exhibit 126: Ascentage Pharma Group International - Overview
  • Exhibit 127: Ascentage Pharma Group International - Product / Service
  • Exhibit 128: Ascentage Pharma Group International - Key offerings
  • 12.7 AstraZeneca Plc
  • Exhibit 129: AstraZeneca Plc - Overview
  • Exhibit 130: AstraZeneca Plc - Product / Service
  • Exhibit 131: AstraZeneca Plc - Key news
  • Exhibit 132: AstraZeneca Plc - Key offerings
  • 12.8 BeiGene Ltd.
  • Exhibit 133: BeiGene Ltd. - Overview
  • Exhibit 134: BeiGene Ltd. - Business segments
  • Exhibit 135: BeiGene Ltd. - Key offerings
  • Exhibit 136: BeiGene Ltd. - Segment focus
  • 12.9 Bio Techne Corp.
  • Exhibit 137: Bio Techne Corp. - Overview
  • Exhibit 138: Bio Techne Corp. - Business segments
  • Exhibit 139: Bio Techne Corp. - Key news
  • Exhibit 140: Bio Techne Corp. - Key offerings
  • Exhibit 141: Bio Techne Corp. - Segment focus
  • 12.10 Biorbyt Ltd.
  • Exhibit 142: Biorbyt Ltd. - Overview
  • Exhibit 143: Biorbyt Ltd. - Product / Service
  • Exhibit 144: Biorbyt Ltd. - Key offerings
  • 12.11 Bristol Myers Squibb Co.
  • Exhibit 145: Bristol Myers Squibb Co. - Overview
  • Exhibit 146: Bristol Myers Squibb Co. - Product / Service
  • Exhibit 147: Bristol Myers Squibb Co. - Key news
  • Exhibit 148: Bristol Myers Squibb Co. - Key offerings
  • 12.12 F. Hoffmann La Roche Ltd.
  • Exhibit 149: F. Hoffmann La Roche Ltd. - Overview
  • Exhibit 150: F. Hoffmann La Roche Ltd. - Business segments
  • Exhibit 151: F. Hoffmann La Roche Ltd. - Key news
  • Exhibit 152: F. Hoffmann La Roche Ltd. - Key offerings
  • Exhibit 153: F. Hoffmann La Roche Ltd. - Segment focus
  • 12.13 Merck and Co. Inc.
  • Exhibit 154: Merck and Co. Inc. - Overview
  • Exhibit 155: Merck and Co. Inc. - Business segments
  • Exhibit 156: Merck and Co. Inc. - Key news
  • Exhibit 157: Merck and Co. Inc. - Key offerings
  • Exhibit 158: Merck and Co. Inc. - Segment focus
  • 12.14 Novartis AG
  • Exhibit 159: Novartis AG - Overview
  • Exhibit 160: Novartis AG - Business segments
  • Exhibit 161: Novartis AG - Key offerings
  • Exhibit 162: Novartis AG - Segment focus
  • 12.15 Santa Cruz Biotechnology Inc.
  • Exhibit 163: Santa Cruz Biotechnology Inc. - Overview
  • Exhibit 164: Santa Cruz Biotechnology Inc. - Product / Service
  • Exhibit 165: Santa Cruz Biotechnology Inc. - Key offerings
  • 12.16 Seagen Inc.
  • Exhibit 166: Seagen Inc. - Overview
  • Exhibit 167: Seagen Inc. - Product / Service
  • Exhibit 168: Seagen Inc. - Key offerings
  • 12.17 Servier
  • Exhibit 169: Servier - Overview
  • Exhibit 170: Servier - Business segments
  • Exhibit 171: Servier - Key offerings
  • Exhibit 172: Servier - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 173: Inclusions checklist
  • Exhibit 174: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 175: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 176: Research methodology
  • Exhibit 177: Validation techniques employed for market sizing
  • Exhibit 178: Information sources
  • 13.5 List of abbreviations
  • Exhibit 179: List of abbreviations